Program Book - Peripheral Blockers as Treatments

Skip Navigation

The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse

Archives of the National Institute on Drug Abuse web site

Search the NIDA Archives

Program List

Click on title to see abstract, click on speaker's name to view biography

Monday, April 27, 1998
8:30 a.m. - 9:00 a.m.	Registration
9:00 a.m. - 9:05 a.m.	Opening Remarks	Steven Sparenborg, Ph.D. Medications Development Division National Institute on Drug Abuse
9:05 a.m. - 9:15 a.m.	Welcome	Richard A. Millstein, J.D. Deputy Director, National Institute on Drug Abuse
9:15 a.m. - 9:45 a.m.	Introductory Lecture: Immunological Approaches to the Treatment of Drug Dependence: Lessons From the Past	Charles R. Schuster, Ph.D. Wayne State University
9:45 a.m. - 10:15 a.m.	Keynote Address: Rational Design and Development of Protein-Based Therapies for Drug Abuse	S. Michael Owens, Ph.D. University of Arkansas for Medical Sciences
	Cocaine Catalytic Antibodies Session Chair, Jamie Biswas, Ph.D. Medications Development Division National Institute on Drug Abuse
10:15 a.m. - 10:45 a.m.	Anti-Cocaine Catalytic Antibodies	Donald W. Landry, M.D., Ph.D. Columbia University College of Physicians and Surgeons
10:45 a.m. - 11:00 a.m.	Break
11:00 a.m. - 11:30 a.m.	The Effects of Anti-Cocaine Antibodies on Cardiovascular, Locomotor, Reinforcing, and Lethal Effects of Cocaine in Rodents	Gail D. Winger, Ph.D. University of Michigan
11:30 a.m. - 12:00 p.m.	Development of Catalytic Antibodies for Cocaine	John Cashman, Ph.D. Human BioMolecular Research Institute
12:00 p.m. - 1:15 p.m.	Lunch (on your own)
1:15 p.m. - 1:45 p.m.	Basics of Antibody Catalysis	Kim D. Janda, Ph.D. The Scripps Research Institute
1:45 p.m. - 2:15 p.m.	Discussion
	Antibodies Session I Chair, Richard Hawks, Ph.D. Medications Development Division National Institute on Drug Abuse
2:15 p.m. - 2:30 p.m.	A Little Chemistry and Molecular Biology in Regards to Immunopharmacological Protocols in the Abatement of Cocaine Abuse and Addiction	Kim D. Janda, Ph.D. The Scripps Research Institute
2:30 p.m. - 3:00 p.m.	Immunization as a Therapeutic Strategy Against Cocaine Abuse	M. Rocio A. Carrera The Scripps Research Institute
3:00 p.m. - 3:15 p.m.	Break
3:15 p.m. - 3:45 p.m.	Therapeutic Vaccine for the Treatment of Cocaine Addiction	Barbara S. Fox, Ph.D. ImmuLogic Pharmaceutical Corporation
3:45 p.m. - 4:15 p.m.	Evaluation of Anti-Cocaine Antibodies and a Cocaine Vaccine in a Rat Self-Administration Model	Kathleen M. Kantak, Ph.D. Boston University
4:15 p.m. - 4:45 p.m.	Towards a Passive Immunotherapy for Cocaine Addiction	Andrew B. Norman, Ph.D. University of Cincinnati School of Medicine
4:45 p.m. - 5:15 p.m.	Development of a Vaccine for Treatment of Nicotine Dependence	Marion Kasaian, Ph.D. ImmuLogic Pharmaceutical Corporation
5:15 p.m. - 5:45 p.m.	Discussion
5:45 p.m.	Adjournment

Tuesday, April 28, 1998
	Antibodies Session II Chair, David McCann, Ph.D. Medications Development Division National Institute on Drug Abuse
8:30 a.m. - 9:00 a.m.	Is a Cocaine Anti-Idiotypic Vaccine Feasible?	Mariangela Segre, D.Sc. University of Illinois
9:00 a.m. - 9:30 a.m.	Effects of Active Immunization on Nicotine Distribution in Rats	Paul Pentel, M.D. University of Minnesota
9:30 a.m. - 10:00 a.m.	Use of a Drug Class-Specific Monoclonal Fab to Treat Phencyclidine Abuse and Overdose In a Rat Model	S. Michael Owens, Ph.D. University of Arkansas for Medical Sciences
10:00 a.m. - 10:15 a.m.	Discussion
10:15 a.m. - 11:00 a.m.	Poster Presentations and Break
	Enzyme Enhancements Session Chair, Betty Tai, Ph.D. Medications Development Division National Institute on Drug Abuse
11:00 a.m. - 11:30 a.m.	Enhancing Cocaine Metabolism With Butyrylcholinesterase as an Approach to Cocaine Addiction Treatment	David A. Gorelick, M.D., Ph.D. National Institute on Drug Abuse
11:30 a.m. - 12:00 p.m.	Attenuation of Cocaine's Activity by Butyrylcholinesterase (BChE)	Gilberto N. Carmona National Institute on Drug Abuse
12:00 p.m. - 1:00 p.m.	Lunch (on your own)
1:00 p.m. - 1:30 p.m.	Effect of JTP-4819 on Cocaine Metabolism	Kazuo Matsubara, M.D. Asahikawa Medical College Hospital
1:30 p.m. - 2:00 p.m.	The Development of Xenobiotic Scavengers by Protein Engineering	Clarence A. Broomfield, Ph.D. U.S. Army Medical Research Institute of Chemical Defense
2:00 p.m. - 2:30 p.m.	An Improved Cocaine Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase Is Fourfold More Efficient	Oksana Lockridge, Ph.D. University of Nebraska Medical Center
2:30 p.m. - 2:45 p.m.	Novel Cocaine Esterases	John Cashman, Ph.D. Human BioMolecular Research Institute
2:45 p.m. - 3:15 p.m.	Discussion
3:15 p.m.	Closing and Adjournment

[Index]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. .